HERTFORDSHIRE, England, PITTSBURGH and SYDNEY, July 8, 2019 – Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) and medical device manufacturer Atomo Diagnostics today announced that the Mylan HIV Self Test, a handheld in vitro HIV rapid diagnostic test for self-testing, has received Prequalification approval by the World Health Organization (WHO...

HERTFORDSHIRE, England, PITTSBURGH and SYDNEY, September 24, 2018 – Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) and medical device company Atomo Diagnostics today announced a strategic partnership to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and middle-income countries. The tests will allow...

Sydney, Australia and Woodstock, England – 05 June 2018 | Atomo Diagnostics and Owen Mumford Ltd have today announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets Owen Mumford acquires exclusive rights to Atomo’s HIV rapid tests for commercialisation under...

Sydney, Australia and Seoul, South Korea – 23 January 2018 | Atomo Diagnostics and Access Bio Inc. today announce a strategic partnership to leverage the respective strengths of both innovative rapid diagnostic test (RDT) companies to expand point of care HIV testing in global markets. ...

Sydney, Australia, 7 December 2017 | Atomo Diagnostics, the world leader in integrated point-of-care rapid diagnostic devices, announced today that its Atomo HIV Self Test has been confirmed as eligible for procurement by organisations entitled to access Global Fund and Unitaid resources. Atomo HIV Self...

Sydney, Australia, May 30, 2017| Multi-award winning medical device innovator Atomo Diagnostics today announced its pioneering HIV self test product has been approved for sale in Kenya. Following successful product evaluations and in-field studies conducted in Kenya by investigators from the Kenya Medical Research Institute (KEMRI), Nairobi, Atomo...

Delighted to welcome new investors for 2017, earlier this month Atomo Diagnostics announced backing from Grand Challenges Canada (GCC). Investment from the Canadian Government-funded agency totalling US$1 million (A$1.31 million, C$1.32 million), in recognition of a ‘bold idea with big impact in global health’, will help...

SYDNEY, Australia, 1 February  2017: Medical device innovator Atomo Diagnostics today announced it had received US$1 million (A$1.31 million, C$1.32 million) in financing from Grand Challenges Canada to support its continued business operations. Funded by the Government of Canada, Grand Challenges Canada is dedicated to supporting Bold...